Adiposis Dolorosa
Adiposis Dolorosa is a widespread, enduring skin condition that leads to the development of itchy, scaly rashes, typically appearing on the knees, elbows, trunk, and scalp. This chronic disorder is currently incurable. For advancing and accelerating Adiposis Dolorosa research, specialized drug and therapy development services are essential. Our company is fully equipped to meet your needs in Adiposis Dolorosa therapy development.
Background of Adiposis Dolorosa
Adiposis Dolorosa is a chronic autoimmune inflammatory disease affecting around 125 million people globally. It is characterized by red, scaly patches on the skin and has been recognized for its systemic impacts beyond the skin, including associations with cardiovascular, gastrointestinal, and mental health conditions. The prevalence of Adiposis Dolorosa varies worldwide, estimated between 0.33% and 0.6% across different populations.
Pathogenesis of Adiposis Dolorosa
The pathogenesis of Adiposis Dolorosa, also known as Dercum's disease, remains poorly understood. It is characterized by painful subcutaneous growths of adipose tissue, which are often accompanied by systemic symptoms such as fatigue, depression, and cognitive impairment. The disease is thought to have an autosomal dominant inheritance pattern with variable penetrance.
Fig. 1 Histopathological findings of Dercum's disease. (Mosbeh, A., et al., 2023)Diagnosis Development of Adiposis Dolorosa
The development of diagnostic methods for Adiposis Dolorosa is evolving, with a combination of evaluation, advanced imaging, genetic studies, and multidisciplinary approaches enhancing diagnostic accuracy. Studies have suggested that certain inflammatory markers might be elevated in Adiposis Dolorosa, providing a potential diagnostic tool.
Therapy Development of Adiposis Dolorosa
Small molecule drugs, which are low molecular weight compounds, have been explored for their potential to modulate biological processes associated with Adiposis Dolorosa. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen and naproxen are often used to manage pain and inflammation, though their efficacy can be limited.
Monoclonal antibodies have shown great potential in treating various diseases, including those with an inflammatory component. Adalimumab targets tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine, and has been used in autoimmune diseases like rheumatoid arthritis, showing potential in reducing pain and inflammation in Adiposis Dolorosa.
Gene therapy holds potential for addressing the genetic and molecular basis of Adiposis Dolorosa. CRISPR/Cas9, a revolutionary gene-editing technology, allows for precise modifications of the genome and is being explored to correct genetic mutations contributing to the disease.
Cell therapies offer an innovative approach for Adiposis Dolorosa. Mesenchymal Stem Cells (MSCs) possess anti-inflammatory and regenerative properties, and trials have shown they can reduce inflammation and pain in various conditions, suggesting potential benefits for Adiposis Dolorosa.
Our Services
Our company embraces a partnership-driven approach. We work closely with clients to develop customized, innovative Adiposis Dolorosa therapy strategies and provide strong support throughout the process.
Platforms of Adiposis Dolorosa Therapy Development
Animal Models of Adiposis Dolorosa
We possess established expertise in developing and using animal models that accurately replicate the disease characteristics and therapeutic responses. These models allow us to assess the safety and efficacy of potential therapies.
| Non-Genetically Engineering Models | ||
| We offer a variety of models tailored to specific research needs related to Adiposis Dolorosa. These models enable researchers to simulate and investigate the complex biological processes involved in Adiposis Dolorosa. | ||
| Optional Models |
|
|
| Genetically Engineered Models | ||
| Our proficiency in genetic engineering techniques, including CRISPR/Cas9 technology, enables us to create precise and reliable models that replicate the genetic alterations seen in Adiposis Dolorosa. | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Non-human primates, Others | |
Additionally, we can offer other comprehensive Animal models services that focus on specific signaling pathways and molecular targets.
If our services interest you, please contact us at your earliest convenience for more details.
References
- Mosbeh, A., et al., "Dercum's Disease: A Rare Disease of Painful Fatty Lumps." Cureus, (2023). 15(11): p. e48615.
- Eliason, A.H., et al., "Adiposis Dolorosa Pain Management." Fed Pract, (2019). 36(11): p. 529-533.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.